Opioids are used across a wide range of medical situations, from post-surgical recovery and cancer pain to less obvious applications like suppressing a stubborn cough or easing severe breathlessness in advanced disease. Their primary role remains pain relief, where they act on receptors in the brain and spinal cord to dampen pain signals. But the story of how and when opioids are actually prescribed has shifted dramatically over the past decade, driven by growing evidence that their benefits for some conditions are far more modest than once assumed and their risks are far more serious.
How Opioids Dampen Pain Signals
Your body has its own built-in pain-management system. Naturally produced molecules called enkephalins and endorphins bind to opioid receptors throughout the nervous system to regulate pain, mood, and stress responses.1PubMed Central. Enkephalins and Pain Modulation: Mechanisms of Action and Therapeutic Perspectives Opioid medications hijack this same system. They bind to the same receptors, particularly the mu-opioid receptor, and amplify the effect well beyond what the body produces on its own.
At the cellular level, opioids reduce the release of chemical messengers that carry pain signals between nerve cells. They do this by affecting ion channels in nerve cell membranes, which quiets the electrical activity that would otherwise relay a pain message from, say, a surgical incision up to the brain.2BJA Open. Opioids and opioid receptors; understanding pharmacological mechanisms as a key to therapeutic advances and mitigation of the misuse crisis They also boost the brain’s own descending pathways that suppress pain. The combined effect is powerful: opioids don’t just block pain at one point but intervene at multiple levels of the nervous system simultaneously.
The term “opioid” covers a broad family. Natural opiates like morphine and codeine come from the opium poppy. Semi-synthetic versions like oxycodone and hydromorphone are chemically modified from those plant compounds. Fully synthetic opioids like fentanyl and methadone are designed from scratch in laboratories.3PubMed Central. Synthetic opioids: a review and clinical update Despite their different origins, all of them interact with the same set of opioid receptors to produce their effects.
Acute and Surgical Pain
The clearest medical case for opioids is short-term pain after surgery, a severe injury, or a medical procedure. Pain in the first hours and days after an operation can be intense, and opioids remain a standard part of the toolkit for managing it. That said, prescribing practices have changed considerably. Surgeons now aim to use the smallest effective amount for the shortest time rather than sending patients home with large supplies of pills.
An expert panel reviewing 20 common surgical procedures found that for every single one, the minimum recommended number of opioid tablets was zero, meaning some patients can recover without opioids at all. The panel recommended ibuprofen for all patients unless it was medically unsafe. When opioids were needed, the recommended maximum varied by procedure, with a median of about 12 to 13 tablets. For three of the twenty procedures, the panel recommended no opioid tablets at all.4PubMed Central. Opioid-Prescribing Guidelines for Common Surgical Procedures: An Expert Panel Consensus This represents a significant departure from earlier norms, when patients routinely received prescriptions for 30 or more tablets after minor procedures.
Chronic Non-Cancer Pain
Using opioids for long-lasting pain conditions like lower back pain, osteoarthritis, and fibromyalgia is where the evidence becomes genuinely thin and the controversy runs deepest. Opioids do provide some pain reduction in the short term for these conditions, but the benefit is smaller than many people expect. A large meta-analysis of 42 randomized trials following patients for three months or longer found that opioids reduced pain compared to placebo, but the average reduction was less than one centimeter on a ten-centimeter pain scale.5JAMA. Opioids for Chronic Noncancer Pain: A Systematic Review and Meta-analysis That is a real but modest effect, and for many patients it falls below the threshold they would consider meaningful.
The longer-term picture is even less encouraging. The American Academy of Neurology concluded that while there is evidence for short-term pain relief, there is no substantial evidence that opioids maintain pain relief or improve function over long periods without serious risk of overdose, dependence, or addiction.6PubMed. Opioids for chronic noncancer pain: a position paper of the American Academy of Neurology A separate systematic review conducted for the National Institutes of Health reached a similar conclusion: the evidence is insufficient to determine whether long-term opioid therapy actually improves chronic pain and function, while the evidence clearly supports dose-dependent risk for serious harms.7PubMed. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop
This doesn’t mean no one with chronic pain should ever take an opioid. Some patients with severe, treatment-resistant pain do benefit, and abrupt discontinuation can itself cause harm. But the evidence argues against opioids as a first-line or routine approach for most chronic non-cancer pain conditions.
Cancer Pain and Palliative Care
Cancer pain is a different clinical world. Tumors can invade bone, compress nerves, and trigger inflammatory cascades that produce severe, relentless pain. Roughly three quarters of cancer patients with significant pain require opioid treatment.8PubMed Central. Cancer pain management-current status The World Health Organization’s analgesic ladder, which guides clinicians to start with non-opioid painkillers and escalate to stronger opioids as needed, has been a cornerstone of cancer pain management for decades.9PubMed. Management of breakthrough pain in patients with cancer
In palliative and end-of-life settings, the goals shift. The priority becomes comfort and quality of remaining life, and the risk calculus changes. Concerns about long-term dependence carry less weight when someone has a terminal illness, and opioids are used more liberally. Morphine, oxycodone, hydromorphone, and fentanyl patches are all common in this context, often titrated upward until pain is adequately controlled.
Uses Beyond Pain
Opioids affect more than just pain pathways, and medicine has taken advantage of some of those other effects for decades.
Cough Suppression
Codeine has been used as a cough suppressant for over a century. Opioids suppress cough by acting on the brainstem’s cough center through mu and kappa opioid receptors.10PubMed Central. Central and peripheral mechanisms of narcotic antitussives: codeine-sensitive and -resistant coughs Dextromethorphan, found in many over-the-counter cold medicines, is technically an opioid derivative, though it has been engineered to suppress cough without producing the euphoria or pain relief of traditional opioids. When a cough is severe and persistent enough that standard remedies fail, prescription codeine or hydrocodone-based syrups are sometimes used, though their typical side effects of sedation, constipation, and nausea limit routine use.
Diarrhea
Loperamide, sold as Imodium, is a mu-opioid receptor agonist that works locally in the gut to slow intestinal motility and reduce fluid secretion.11PubMed Central. Modulation of gastrointestinal function by MuDelta, a mixed µ opioid receptor agonist/ µ opioid receptor antagonist It was deliberately designed not to cross into the brain in meaningful amounts, so it controls diarrhea without causing pain relief, sedation, or euphoria at normal doses. It’s one of the most widely used opioids in the world, though most people who take it have no idea they’re using one.
Breathlessness in Advanced Disease
Opioids can relieve the sensation of suffocating breathlessness that accompanies advanced lung disease, heart failure, and some cancers. Low-dose oral morphine is increasingly recognized as a standard treatment for this symptom. A narrative review found level-one evidence supporting the use of low-dose sustained-release morphine for breathlessness in people who are not already taking opioids, at daily doses of roughly 10 to 30 milligrams.12BMJ Supportive & Palliative Care. Opioids for breathlessness: a narrative review A Cochrane review also found some benefit for oral or parenteral opioids in this context, though the evidence quality was rated low and participant numbers were small.13Cochrane Database of Systematic Reviews. Opioids for the palliation of breathlessness in advanced disease and terminal illness The mechanism isn’t entirely about pain; opioids seem to reduce the brain’s distress response to air hunger itself, making the sensation of not being able to breathe feel less overwhelming.
Side Effects and Life-Threatening Risks
The side effects of opioids are a direct consequence of how they work. Opioid receptors aren’t limited to pain pathways. They sit throughout the gut, the brainstem’s breathing centers, and the brain’s reward circuitry, so drugs that activate them produce effects in all of those areas simultaneously.
Constipation is the most common side effect, and unlike most opioid side effects, the body does not develop tolerance to it over time. Mu-opioid receptors in the stomach and colon, when activated, reduce gut motility and fluid secretion, effectively slowing everything down.14Journal of Neurogastroenterology and Motility. Opioid-induced Constipation: Old and New Concepts in Diagnosis and Treatment For patients on long-term opioids, constipation often becomes a condition that requires its own treatment.
The most dangerous acute risk is respiratory depression. Opioids slow breathing by acting on brainstem circuits that control respiratory rate, particularly a cluster of neurons called the preBötzinger Complex that sets the basic rhythm of breathing.15PubMed Central. Multi-Level Regulation of Opioid-Induced Respiratory Depression At high doses, or when opioids are combined with other sedating drugs like benzodiazepines or alcohol, breathing can slow to the point of fatal oxygen deprivation. Research in mice has identified specific mu-opioid-receptor-expressing neurons in the lateral parabrachial nucleus whose activity is tightly correlated with breathing rate, and whose suppression by morphine directly produces the respiratory slowdown seen in overdose.16PubMed Central. Neural basis of opioid-induced respiratory depression and its rescue
Naloxone, known by the brand name Narcan, reverses overdose by competitively displacing opioid molecules from the mu-opioid receptor.17PubMed Central. Clinical Pharmacokinetics and Pharmacodynamics of Naloxone It works within minutes when given by injection or nasal spray, but because its effects wear off faster than many opioids, repeated doses or ongoing monitoring may be needed. The widespread availability of naloxone in pharmacies and community programs has become a central harm-reduction strategy.
When Opioids Make Pain Worse
One of the more counterintuitive complications of long-term opioid use is a phenomenon called opioid-induced hyperalgesia, where the medication paradoxically increases a person’s sensitivity to pain. This is distinct from tolerance, where you need a higher dose to get the same relief. With hyperalgesia, you actually experience more pain than you would if you weren’t taking the drug at all.
The exact mechanism isn’t fully worked out, but it appears to involve changes in the nervous system that amplify pain signaling pathways. The most widely discussed explanation involves activation of a particular set of receptors in the spinal cord that ramp up the nervous system’s responsiveness to painful stimuli.18PubMed. A comprehensive review of opioid-induced hyperalgesia The clinical challenge is distinguishing hyperalgesia from tolerance. If escalating the dose makes pain worse rather than better, hyperalgesia may be the problem, and the appropriate response is to reduce or rotate opioids rather than increase them.19The Clinical Journal of Pain. Opioid-induced Hyperalgesia in Humans: Molecular Mechanisms and Clinical Considerations
Reducing Opioid Use After Surgery
One of the most active areas in modern pain management is figuring out how to use fewer opioids after surgery without leaving patients in pain. The strategy, broadly called multimodal analgesia, involves combining several non-opioid medications and techniques so that each one handles a different piece of the pain puzzle.
The approach works. A large analysis found that patients who received multimodal analgesia reported pain scores about one point lower on a ten-point scale compared to those who received no multimodal combination, and inpatients used meaningfully fewer opioid equivalents after surgery.20Regional Anesthesia & Pain Medicine. Optimal multimodal analgesia combinations to reduce pain and opioid use following non-cardiac surgery: an instrumental variable analysis A separate systematic review found that overall, multimodal approaches reduce opioid intake in the postoperative setting across multiple types of procedures.21PubMed Central. Multimodal Analgesia in the Perioperative Period of Major Surgeries: An In-depth Analysis
The specific agents used vary, but several non-opioid drugs have solid evidence behind them. A network meta-analysis found that dexmedetomidine, ketamine, lidocaine, magnesium, and gabapentin all significantly reduced postoperative opioid consumption compared to placebo.22PubMed. Efficacy of nonopioid analgesics and adjuvants in multimodal analgesia for reducing postoperative opioid consumption and complications in obesity: a systematic review and network meta-analysis Regional nerve blocks, local anesthetic infusions, and simple anti-inflammatory drugs like ibuprofen and acetaminophen round out the toolkit. The idea is that no single agent replaces opioids entirely, but the combination can reduce the amount needed to something much smaller and safer.
How Prescribing Guidelines Changed the Landscape
The 2016 CDC guideline for opioid prescribing marked a watershed moment. It recommended against opioids as first-line therapy for chronic pain, urged clinicians to start with the lowest effective dose, and set soft thresholds that prompted extra caution at higher doses. The effect on actual prescribing was substantial: by the end of 2018, the guideline was associated with roughly a 20-percentage-point drop in the rate of patients receiving at least one opioid prescription for conditions like osteoarthritis and back or neck pain.23PubMed Central. CDC Guideline For Opioid Prescribing Associated With Reduced Dispensing To Certain Patients With Chronic Pain The reduction was somewhat smaller for conditions like fibromyalgia and headache.
The guideline was updated in 2022 to soften some of the rigid dose thresholds that clinicians had begun applying too inflexibly, sometimes forcibly tapering patients who had been stable on long-term opioids for years. The updated version emphasizes individualized decisions and warns against abrupt discontinuation, reflecting hard lessons about the unintended harms of overly aggressive deprescribing. Patients who were forcibly tapered sometimes turned to illicit opioids or experienced worsening pain and mental health crises.
Why the Same Dose Affects People Differently
If you’ve ever noticed that one person gets adequate pain relief from a dose that barely touches another person’s pain, genetics is a major reason. Variations in genes that encode opioid receptors, drug-metabolizing enzymes, and pain-signaling molecules all influence how an individual responds to a given opioid and dose.24PubMed Central. Genetics and Opioids: Towards More Appropriate Prescription in Cancer Pain
One of the best-studied examples involves a common variant in the gene for the mu-opioid receptor itself. A meta-analysis found that people carrying the 118G variant of this gene consumed more opioids to achieve pain relief and reported higher pain scores than people with the more common version of the gene, at least in the first 24 hours after surgery.25PubMed. The impact of genetic variation on sensitivity to opioid analgesics in patients with postoperative pain: a systematic review and meta-analysis Interestingly, those same carriers experienced less nausea and vomiting, suggesting the variant doesn’t just change potency but reshapes the entire side-effect profile.
Enzyme variations matter too. Codeine, for example, is essentially a prodrug that must be converted to morphine by a liver enzyme to work. People who carry extra copies of the gene for that enzyme convert codeine extremely rapidly and can experience dangerously high morphine levels from a standard dose, while those who lack functional copies get almost no pain relief at all. This kind of variability is why pharmacogenomic testing, though still not routine, is slowly entering clinical practice for pain management.
Medications for Opioid Use Disorder
Opioids are also, somewhat paradoxically, the primary treatment for opioid addiction. Methadone and buprenorphine are long-acting opioids that stabilize the receptor system without producing the intense highs and lows of short-acting drugs like heroin or crushed oxycodone. Both reduce cravings, prevent withdrawal symptoms, and lower the risk of overdose death.
A small randomized trial of patients with both chronic pain and opioid addiction found that those treated with either methadone or buprenorphine for six months experienced a roughly 13% reduction in pain among those who remained in the study. No patients in the methadone group reported illicit opioid use at follow-up, compared with five in the buprenorphine group.26PubMed Central. A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction The study was small and preliminary, but it illustrates the dual role these medications can play: treating addiction while also providing some pain relief for patients who genuinely have both conditions.
Buprenorphine works differently from full opioid agonists. It’s a partial agonist, meaning it activates the mu-opioid receptor enough to prevent withdrawal and reduce cravings but has a ceiling effect that limits euphoria and, critically, limits respiratory depression. This pharmacological profile makes it considerably safer in overdose situations than methadone or full agonists.
The Search for Safer Opioids
A significant thread of current research aims to decouple opioid pain relief from its most dangerous side effects. The leading concept is called biased agonism. Traditional opioids activate the mu-opioid receptor and trigger two major signaling cascades inside the cell: one mediated by G proteins and one mediated by a molecule called beta-arrestin. The hypothesis driving new drug design is that the G protein pathway is primarily responsible for pain relief, while the beta-arrestin pathway contributes more to respiratory depression, constipation, and tolerance.27PubMed Central. Biased Opioid Receptor Agonists: Balancing Analgesic Efficacy and Side-Effect Profiles
The goal, then, is to design opioids that preferentially activate the G protein pathway while minimizing beta-arrestin signaling. Several such compounds have been developed and tested.28PubMed Central. Biased ligands at opioid receptors: Current status and future directions Oliceridine, the first biased agonist to reach the market, was approved for intravenous use in hospitals. Early results suggested it might cause less nausea and respiratory depression than morphine, though the clinical advantages turned out to be more modest than preclinical data predicted. The hypothesis itself has come under scrutiny, with some researchers questioning whether the clean separation between G protein and beta-arrestin pathways holds up as neatly in real physiology as it does in cell cultures. Still, the approach represents one of the most active frontiers in analgesic drug development, and newer compounds are working through clinical trials.